BioCentury
ARTICLE | Clinical News

KD019: Phase Ib/IIa started

June 9, 2014 7:00 AM UTC

Kadmon began an open-label, U.S. Phase Ib/IIa trial of once-daily oral KD019 in combination with Herceptin trastuzumab every 3 weeks in up to 38 patients with HER2-positive breast cancer who have received prior trastuzumab therapy. The Phase Ib portion, which will enroll patients with or without brain metastases, will evaluate multiple ascending-doses of 150, 250 and 300 mg KD019 to determine the MTD. The Phase IIa portion will evaluate the MTD but will limit enrollment to patients with brain metastases progressing after radiation therapy. ...